Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis

Tsui, Florence W. L.; Tsui, Hing Wo; Heras, Facundo Las; Pritzker, Kenneth P.H.; Inman, Robert D.

doi:10.1136/annrheumdis-2013-203630

Cited by 59 publications

(51 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the potential biomarkers of bone remodeling in AS, BMP7 beside DKK-1 (dickkopf-1) displayed significant time alterations and correlative interactions during an anti-TNF treatment [52]. In AS patients IgG autoantibodies against noggin were reported at a higher level than in healthy individuals which could contribute to neo-ossification in those patients [53]. Inhibition of BMP signalling by noggin results in the protection against arthritis and ankylosis, not only in a preventive setting in which gene transfer was performed before the onset of the disease but also in a therapeutic setup where gene transfer was performed at the onset of clinical symptoms.…”

Section: Bmps In Inflammatory Skeletal Diseasementioning

confidence: 98%

Bone morphogenetic proteins in inflammation, glucose homeostasis and adipose tissue energy metabolism

Grgurević

Christensen

Schulz

et al. 2016

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Section: Bmps In Inflammatory Skeletal Diseasementioning

confidence: 98%

Bone morphogenetic proteins in inflammation, glucose homeostasis and adipose tissue energy metabolism

Grgurević

Christensen

Schulz

et al. 2016

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

“…However, despite some obvious clinical advantages, they have not made their way into clinical routine. Also, circulating serum proteins that indicate skeletal involvement and inflammation as an extraintestinal manifestation of IBD have provided promising results [60, 61••, 62, 63••, 64••, [65][66][67]. While those novel markers certainly are scientifically interesting, the important question to be raised always is, Are those biomarkers helpful for treatment decisions and for stratifying the therapy?…”

Section: Introductionmentioning

confidence: 98%

Clinical Utility of Biomarkers in IBD

Rogler

Biedermann

2015

Curr Gastroenterol Rep

View full text Add to dashboard Cite

There is no gold standard for the diagnosis and monitoring of inflammatory bowel diseases (IBD). Biomarkers are useful tools for the management of patients suffering from IBD. However, they should be used only when their additional information is useful for clinical decision-making. In principal, four situations during the management of an individual IBD patient can be discriminated from a clinical standpoint in which biomarkers provide useful information. First, biomarkers may be helpful when the diagnosis of IBD is established and aid in the discrimination between ulcerative colitis (UC) and Crohn's disease (CD) is necessary. Second, biomarkers may be helpful in the prognostic evaluation of IBD severity or disease behavior and for early decisions on the best treatment. The third situation in which biomarkers are useful is the evaluation of disease activity during the disease course, for monitoring and for guidance of ongoing treatment. Finally, the fourth typical situation when biomarkers are of value is after surgery to predict or diagnose a relapse of the disease. From a clinical point of view, it may be more useful to discuss specific biomarkers and their individual value and impact in these four prototypic situations than to sum up advantages and disadvantages for each biomarker isolated from the clinical situation. Therefore, this overview is structured in chapters reflecting those four typical situations during the disease course of IBD patents to critically evaluate the potential and value of each of the biomarkers in the specific situation.

show abstract

“…In contrast, we showed that NOG treatment of ank/ank mice led to more severe ankylosis, with concurrent generation of high levels of immunoglobulin (Ig)-G immune complexes (ICs) in which the autoantigens are either NOG (a bone morphogenetic protein-signaling antagonist) or SOST (a Wnt/β-catenin signaling antagonist) 93. These results from the mutant ank/ank mice led to our novel finding of similar NOG/SOST IgG ICs in humans, and AS patients have significantly elevated serum levels of these ICs 93. An intriguing possibility is that ICs involving autoantibodies against NOG and SOST at their interacting sites may mimic the inhibitory interaction that naturally occurs between these two proteins.…”

Section: Animal Models With Axial Ankylosismentioning

confidence: 99%

The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis

Tsui

Akram

et al. 2014

TACG

Self Cite

View full text Add to dashboard Cite

Ankylosing spondylitis (AS) is a complex disease involving multiple risk factors, both genetic and environmental. AS patients are predominantly young men, and the disease is characterized by inflammation and ankylosis, mainly at the cartilage–bone interface and enthesis. HLA-B27 has been known to be the major AS-susceptibility gene for more than 40 years. Despite advances made in the past few years, progress in the search for non-human leukocyte antigen susceptibility genes has been hampered by the heterogeneity of the disease. Compared to other complex diseases, such as inflammatory bowel disease (IBD), fewer susceptibility loci have been identified in AS. Furthermore, non-major histocompatibility-complex susceptibility loci discovered, such as ERAP1 and IL23R, are likely contributors to joint inflammation. Identification and confirmation of functional variants remains a significant challenge of investigations involving genome-wide association studies (GWAS). It remains unclear why none of the AS-susceptibility genes identified in GWAS appear to be directly involved in the ankylosing process. Numerous reviews have recently been published on the genetics of AS. Therefore, aside from a brief summary of what AS GWAS has successfully achieved thus far, this review will focus on directions that could address unanswered questions raised by GWAS.

show abstract

Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis

Cited by 59 publications

References 30 publications

Bone morphogenetic proteins in inflammation, glucose homeostasis and adipose tissue energy metabolism

Bone morphogenetic proteins in inflammation, glucose homeostasis and adipose tissue energy metabolism

Clinical Utility of Biomarkers in IBD

The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis

Contact Info

Product

Resources

About